Overexpressed miR-122-5p Promotes Cell Viability, Proliferation, Migration And Glycolysis Of Renal Cancer By Negatively Regulating PKM2

References

• Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84. doi:10.1016/j.eururo.2018.08.03630243799
   PubMed Web of Science ®Google Scholar
• Lenis AT, Donin NM, Johnson DC, et al. Adjuvant therapy for high risk localized kidney cancer: emerging evidence and future clinical trials. J Urol. 2018;199:43–52. doi:10.1016/j.juro.2017.04.09228479237
   PubMed Web of Science ®Google Scholar
• Tan HJ, Shirk JD, Chamie K, Litwin MS, Hu JC. Patient function and the value of surgical care for kidney cancer. J Urol. 2017;197:1200–1207. doi:10.1016/j.juro.2016.12.01227986531
   PubMed Web of Science ®Google Scholar
• Turato C, Fornari F, Pollutri D, et al. MiR-122 targets SerpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma. J Clin Med. 2019;8:e28
   Web of Science ®Google Scholar
• Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2019;69:760–773. doi:10.1002/hep.2980229357190
   PubMed Web of Science ®Google Scholar
• Luna JM, Barajas JM, Teng KY, et al. Argonaute CLIP defines a deregulated miR-122-bound transcriptome that correlates with patient survival in human liver cancer. Mol Cell. 2017;67:400–10.e7. doi:10.1016/j.molcel.2017.06.02528735896
   PubMed Web of Science ®Google Scholar
• Yamane D, Selitsky SR, Shimakami T, et al. Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3 variants. Nucleic Acids Res. 2017;45:4743–4755. doi:10.1093/nar/gkw133228082397
   PubMed Web of Science ®Google Scholar
• Masaki T, Arend KC, Li Y, et al. miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation. Cell Host Microbe. 2015;17:217–228. doi:10.1016/j.chom.2014.12.01425662750
   PubMed Web of Science ®Google Scholar
• Chandimali N, Huynh DL, Zhang JJ, et al. MicroRNA-122 negatively associates with peroxiredoxin-II expression in human gefitinib-resistant lung cancer stem cells. Cancer Gene Ther. 2019;26:292–304. doi:10.1038/s41417-018-0050-130341415
   PubMed Web of Science ®Google Scholar
• Xu X, Gao F, Wang J, et al. MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biol Ther. 2018;19:427–435. doi:10.1080/15384047.2018.142392529509059
   PubMed Web of Science ®Google Scholar
• Byrnes CC, Jia W, Alshamrani AA, Kuppa SS, Murph MM. miR-122-5p expression and secretion in melanoma cells is amplified by the LPAR3 SH3-binding domain to regulate Wnt1. Mol Cancer Res. 2019;17:299–309. doi:10.1158/1541-7786.MCR-18-046030266753
   PubMedGoogle Scholar
• Maierthaler M, Benner A, Hoffmeister M, et al. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int J Cancer. 2017;140:176–187. doi:10.1002/ijc.3043327632639
   PubMed Web of Science ®Google Scholar
• Fan Y, Ma X, Li H, et al. miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating dicer. Int J Cancer. 2018;142:547–560. doi:10.1002/ijc.v142.328921581
   PubMed Web of Science ®Google Scholar
• Jingushi K, Kashiwagi Y, Ueda Y, et al. High miR-122 expression promotes malignant phenotypes in ccRCC by targeting occludin. Int J Oncol. 2017;51:289–297. doi:10.3892/ijo.2017.401628534944
   PubMed Web of Science ®Google Scholar
• Heinemann FG, Tolkach Y, Deng M, et al. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics. 2018;10:11. doi:10.1186/s13148-018-0444-929410711
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Jia L, Huang S, Yin X, Zan Y, Guo Y, Han L. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. Life Sci. 2018;208:123–130. doi:10.1016/j.lfs.2018.07.02730025823
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang M, Jiang H, Liu F, Liu H, Li Y. Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2. Biomed Pharmacother. 2018;105:545–552. doi:10.1016/j.biopha.2018.06.00929886375
   PubMed Web of Science ®Google Scholar
• Zhou Y, Niu W, Luo Y, et al. p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53. Cancer Sci. 2019;110:939–949. doi:10.1111/cas.1392830618169
   PubMed Web of Science ®Google Scholar
• Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 2013;41:917–922. doi:10.1042/BST2013003423863156
   PubMed Web of Science ®Google Scholar
• Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. Cancer Lett. 2015;356:184–191. doi:10.1016/j.canlet.2014.01.03124508027
   PubMed Web of Science ®Google Scholar
• Dayton TL, Jacks T, Vander Heiden MG. PKM2, cancer metabolism, and the road ahead. EMBO Rep. 2016;17:1721–1730. doi:10.15252/embr.20164330027856534
   PubMed Web of Science ®Google Scholar
• Liu F, Ma F, Wang Y, et al. PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis. Nat Cell Biol. 2017;19:1358–1370. doi:10.1038/ncb363029058718
   PubMed Web of Science ®Google Scholar
• Cao Q, Bai P. Role of autophagy in renal cancer. J Cancer. 2019;10:2501–2509. doi:10.7150/jca.2928531258756
   PubMed Web of Science ®Google Scholar
• Shanmugasundaram K, Nayak BK, Friedrichs WE, Kaushik D, Rodriguez R, Block K. NOX4 functions as a mitochondrial energetic sensor coupling cancer metabolic reprogramming to drug resistance. Nat Commun. 2017;8:997. doi:10.1038/s41467-017-01106-129051480
   PubMed Web of Science ®Google Scholar
• Cheng W, Ji S, Zhang H, et al. mTOR activation is critical for betulin treatment in renal cell carcinoma cells. Biochem Biophys Res Commun. 2017;482:1030–1036. doi:10.1016/j.bbrc.2016.11.15327908730
   PubMed Web of Science ®Google Scholar
• Wang J, Sun X. MicroRNA-375 inhibits the proliferation, migration and invasion of kidney cancer cells by triggering apoptosis and modulation of PDK1 expression. Environ Toxicol Pharmacol. 2018;62:227–233. doi:10.1016/j.etap.2018.08.00230098579
   PubMed Web of Science ®Google Scholar
• Szabo Z, Szegedi K, Gombos K, et al. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC. Urol Oncol. 2016;34:533.e21-.e27. doi:10.1016/j.urolonc.2016.06.011
   Web of Science ®Google Scholar
• Strauss P, Marti HP, Beisland C, et al. Expanding the utilization of formalin-fixed, paraffin-embedded archives: feasibility of miR-seq for disease exploration and biomarker development from biopsies with clear cell renal cell carcinoma. Int J Mol Sci. 2018;19. doi:10.3390/ijms19030803
   Web of Science ®Google Scholar
• Lin C, Li Z, Chen P, et al. Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma. Life Sci. 2018;209:481–489. doi:10.1016/j.lfs.2018.08.04430138594
   PubMed Web of Science ®Google Scholar
• Lei Z, Ma X, Li H, et al. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis. Urol Oncol. 2018;36:93.e23-93.e37. doi:10.1016/j.urolonc.2017.09.019
   PubMed Web of Science ®Google Scholar
• Mu W, Hu C, Zhang H, et al. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res. 2015;25:477–495. doi:10.1038/cr.2015.2325698578
   PubMed Web of Science ®Google Scholar
• Wu Q, Liu HO, Liu YD, et al. Decreased expression of hepatocyte nuclear factor 4alpha (Hnf4alpha)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity. J Biol Chem. 2015;290:1170–1185. doi:10.1074/jbc.M114.60120325422324
   PubMed Web of Science ®Google Scholar
• Jin Y, Wang J, Han J, Luo D, Sun Z. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/beta-cadherin signaling pathway. Exp Cell Res. 2017;360:210–217. doi:10.1016/j.yexcr.2017.09.01028890291
   PubMed Web of Science ®Google Scholar
• Bodnar L, Stec R, Cierniak S, et al. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. Ann Oncol. 2015;26:1385–1389. doi:10.1093/annonc/mdv16625962440
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li M, Zhang L, et al. Oncogenic kinase-induced PKM2 tyrosine 105 phosphorylation converts nononcogenic PKM2 to a tumor promoter and induces cancer stem-like cells. Cancer Res. 2018;78:2248–2261. doi:10.1158/0008-5472.CAN-17-272629440169
   PubMed Web of Science ®Google Scholar
• Shiroki T, Yokoyama M, Tanuma N, et al. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism. Cancer Sci. 2017;108:931–940. doi:10.1111/cas.1321128235245
   PubMed Web of Science ®Google Scholar
• Xu Q, Tu J, Dou C, et al. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma. Mol Cancer. 2017;16:178. doi:10.1186/s12943-017-0748-y29262861
   PubMed Web of Science ®Google Scholar
• Mendez-Lucas A, Li X, Hu J, et al. Glucose catabolism in liver tumors induced by c-MYC can be sustained by various PKM1/PKM2 ratios and pyruvate kinase activities. Cancer Res. 2017;77:4355–4364. doi:10.1158/0008-5472.CAN-17-049828630053
   PubMed Web of Science ®Google Scholar
• Qi W, Keenan HA, Li Q, et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat Med. 2017;23:753–762. doi:10.1038/nm.432828436957
   PubMed Web of Science ®Google Scholar
• Huang J, Kong W, Zhang J, et al. c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma. Int J Oncol. 2016;49:1569–1575. doi:10.3892/ijo.2016.362227431728
   PubMed Web of Science ®Google Scholar
• Xu Q, Zhang M, Tu J, Pang L, Cai W, Liu X. MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma. Oncol Rep. 2015;34:2054–2064. doi:10.3892/or.2015.417526252254
   PubMed Web of Science ®Google Scholar